

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/593,173	06/12/2000	Antonio Guarna	1195-003	5454	
75	90 02/12/2003				
James V Costigan Esq Hedman Gibson & Costigan PC 1185 Avenue of the Americas Suite 2003			EXAMINER		
			ROBINSON, BINTA M		
New York, NY 10036-2646			ART UNIT	PAPER NUMBER	
			1625		
			DATE MAILED: 02/12/2003	DATE MAILED: 02/12/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

1,		Application No.	Applicant(s)			
,	•	09/593,173	GUARNA ET AL.			
Office Action Summary		Examiner	Art Unit			
·		Binta M. Robinson	1625			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE I - Externanter - If the - If NC - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	86(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) day and will expire SIX (6) MONTHS from cause the application to become ABANDON	ays will be considered timely. In the mailing date of this communication. IED (35 U.S.C. § 133).			
1)	Responsive to communication(s) filed on					
2a)□		— · is action is non-final.				
3)	Since this application is in condition for allowa		prosecution as to the merits is			
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) <u>1-10 and 18-28</u> is/are pending in the application.						
4a) Of the above claim(s) <u>4-9 and 18-26</u> is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-3,10,27 and 28</u> is/are rejected.						
7)	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement. Application Papers						
9)[The specification is objected to by the Examiner	•				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)⊠ All b)□ Some * c)□ None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 						
Attachmen						
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informa	ry (PTO-413) Paper No(s) I Patent Application (PTO-152)			

Art Unit: 1625

ء سوجي

Detailed Action

The 112, second paragraph rejection of claims 1, 2, 10, 28 at paper no. 13 is withdrawn in light of applicant's amendment at paper no. 15/D. The 112, first paragraph enablement rejection of claim 28 is withdrawn in light of applicant's remarks and amendment at paper no. 15/D.

(new rejections)

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 2, 10, and 28 in part are rejected under 35 U.S.C. 112, first paragraph because the specification does not reasonably provide enablement for the compound of formula I and in claim 1 and all other claims where the radicals are equal to all saturated or aromatic heterocycle rings containing one to three N atoms.

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue". These factors include 1)the breadth of the claims, 2) the nature of the invention, 3) the state of the prior art, 4) the level of one of ordinary skill, 5) the level of predictability in the art 6) the amount of direction provided by the inventor 7) the existence of working examples, and 8) the quantity of experimentation

Art Unit: 1625

needed to make or use the invention based on the content of the disclosure. In re Wands, 858 F. 2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

In terms of the breadth of the claims, R1, R2, R3, R4, and R6 encompasses a much wider Markush grouping of radicals than those radicals tested which consist of hydrogen. 2) the nature of the invention is that these compounds are inhibitors of steroid 5 alpha reductases. 5) the level of predictability in the art was low since only two compounds, compounds 2, 3, 5, 6, 7, 9, 10-octahydro-(1H)-benzo[c]quinolinzi-3-one and 2, 3, 5, 6, 6a, 7, 8,9 –octahydro-(3H)-benzo[c]quinolizin-3-one, were tested for their inhibitory activity on 5 alpha reductase enzyme, where the R1, R2, R3, R4, and R6 moieties are all hydrogen.

The compounds showed an inhibition of greater than 50 %. However, the level of predictability regarding inhibiting activity is low because only these two compounds were tested. No compounds containing 5 nitrogens in a ring, for example were tested, for their inhibition activity. 6) the amount of direction provided by the inventor is poor, because the applicant only conducts tests for two compounds where R1, R2, R3, R4, and R6 is equal to hydrogen. The applicant does not test the whole breadth of compounds encompassing all of the moieties that these particular radicals can be. 7) the applicant only provides working examples for two, compounds 2, 3, 5, 6, 7, 9, 10-octahydro-(1H)-benzo[c]quinolinzi-3-one and 2, 3, 5, 6, 6a, 7, 8,9 –octahydro-(3H)-benzo[c]quinolizin-3-one.

In terms of the 8th Wands factors, undue experimentation would be required to make or use the invention based on the content of the disclosure due to the breadth of

Art Unit: 1625

the claims, the level of predictability in the art of the invention, and the poor amount of direction provided by the inventor. Taking the above factors into consideration, it is not seen where the instant claim is enabled by the instant application.

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim(s) 3 and 27 in part are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- A. In claim 3, page 23, line 1, the phrase "Benzo[c]-quinolizine compounds" is indefinite. It is unclear as to whether or not the applicant is referring to a pharmaceutical composition or a compound. The phrase "A benzo[c]-quinolizine compound" is suggested.
- B. Claim 27 is indefinite because it is dependent on a cancelled claim 11.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Binta M. Robinson whose telephone number is (703) 306-5437. The examiner can normally be reached on M-F (9:30-6:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Alan Rotman can be reached on (703)308-4698. The fax phone numbers for the organization where this application or proceeding is assigned are (703)308-7922 for regular communications and (703)308-7922 for After Final communications.

Art Unit: 1625

Page 5

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-0193.

Binta Robinson

February 7, 2003

ALAN L. ROTMAN SUPERVISORY PATENT EXAMIN

TECHNOLOGY CENTER 1600

Man & Rotman